We are live on ! Find out more
PALI icon

Palisade Bio

5 hedge funds and large institutions have $359K invested in Palisade Bio in 2020 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 5 → 5 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

1.14% less ownership

Funds ownership: 6.91% → 5.77% (-1.1%)

40% less capital inflows, than outflows

Capital inflows: $156K | Capital outflows: $258K

Holders
5
Holders Change
–
Holders Change %
0%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

PALI Hedge Fund Activity: Q1 2020 in Review

5 of the 4,550 institutional investors tracked by Wall St. Rank reported a position in Palisade Bio (PALI) for Q1 2020, worth a combined $359K — down 44% from $644K a quarter earlier.

Fund positioning in PALI was balanced in Q1 2020: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 1 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $108K. The largest seller was Sabby Management, cutting an estimated $255K.

  • 5 institutional investors held Palisade Bio (PALI) as of Q1 2020, unchanged from Q4 2019.
  • Funds reported $359K of Palisade Bio stock for Q1 2020, down 44% quarter-over-quarter.
  • 1 fund opened new Palisade Bio positions in Q1 2020 and 1 closed out, a net change of 0 holders.
  • The largest Palisade Bio buyer in Q1 2020 was Renaissance Technologies, an estimated $108K added.
  • The largest Palisade Bio seller in Q1 2020 was Sabby Management, an estimated $255K sold.

Based on aggregated 13F filings for Q1 2020.